Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study
Lisa M Noguchi, Barbra A Richardson, Jared M Baeten, Sharon L Hillier, Jennifer E Balkus, Z Mike Chirenje, Katherine Bunge, Gita Ramjee, Gonasagrie Nair, Thesla Palanee-Phillips, Pearl Selepe, Ariane van der Straten, Urvi M Parikh, Kailazarid Gomez, Jeanna M Piper, D Heather Watts, Jeanne M Marrazzo, VOICE Study Team, Lisa M Noguchi, Barbra A Richardson, Jared M Baeten, Sharon L Hillier, Jennifer E Balkus, Z Mike Chirenje, Katherine Bunge, Gita Ramjee, Gonasagrie Nair, Thesla Palanee-Phillips, Pearl Selepe, Ariane van der Straten, Urvi M Parikh, Kailazarid Gomez, Jeanna M Piper, D Heather Watts, Jeanne M Marrazzo, VOICE Study Team
Abstract
Background: Several observational studies have reported that HIV-1 acquisition seems to be higher in women who use depot medroxyprogesterone acetate (DMPA) than in those who do not use hormonal contraception. We aimed to assess whether two injectable progestin-only contraceptives, DMPA and norethisterone enanthate (NET-EN), confer different risks of HIV-1 acquisition.
Methods: We included data from South African women who used injectable contraception while participating in theVOICE study, a multisite, randomised, placebo-controlled trial that investigated the safety and efficacy of three formulations of tenofovir for prevention of HIV-1 infection in women between Sept 9, 2009, and Aug 13, 2012. Women were assessed monthly for contraceptive use and incident infection. We estimated the difference in incident HIV-1infection between DMPA and NET-EN users by Cox proportional hazards regression analyses in this prospective cohort. The VOICE trial is registered with ClinicalTrials.gov, NCT00705679.
Findings: 3141 South African women using injectable contraception were included in the present analysis: 1788 (56·9%)solely used DMPA, 1097 (34·9%) solely used NET-EN, and 256 (8·2%) used both injectable types at different times during follow-up. During 2733·7 person-years of follow-up, 207 incident HIV-1 infections occurred (incidence7·57 per 100 person-years, 95% CI 6·61–8·68). Risk of HIV-1 acquisition was higher among DMPA users (incidence 8·62 per 100 person-years, 95% CI 7·35–10·11) than among NET-EN users (5·67 per 100 person-years, 4·35–7·38;hazard ratio 1·53, 95% CI 1·12–2·08; p=0·007). This association persisted when adjusted for potential confoundingvariables (adjusted hazard ratio [aHR] 1·41, 95% CI 1·06–1·89; p=0·02). Among women seropositive for herpes simplex virus type 2 (HSV-2) at enrolment, the aHR was 2·02 (95% CI 1·26–3·24) compared with 1·09 (0·78–1·52)for HSV-2-seronegative women (pinteraction=0·07).
Interpretation: Although moderate associations in observational analyses should be interpreted with caution, thesefi ndings suggest that NET-EN might be an alternative injectable drug with a lower HIV risk than DMPA in high HIV-1 incidence settings where NET-EN is available.
Funding: National Institutes of Health, Mary Meyer Scholars Fund, and the Ruth Freeman Memorial Fund.
Conflict of interest statement
Declaration of interests
BAR has received consultancy fees from Tobira Therapeutics and Theratechnologies. SLH has received consultancy fees from Merck and Symbiomix. JEB has received consultancy fees from Symbiomix. JMM has received consultancy fees from Merck. All other authors declare no competing interests.
Figures
Source: PubMed